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Abstract 
Background: The aim of the current study was to investigate whether the Basidiomycetes fungus Lentinula edodes 
can biosynthesize Se-methyl-seleno-l-cysteine, a seleno-amino acid with strong anticancer activity, and to optimize 
the culture conditions for its biosynthesis. We hypothesize that preparations obtained from Se-methyl-seleno-
l-cysteine-enriched mycelia from this medicinal mushroom would possess stronger cancer-preventive properties 
than current preparations.
Results: By optimizing the concentration of selenium in the culture medium, we increased the mycelial concen-
tration of Se-methyl-seleno-l-cysteine from essentially non-detectable levels to 120 µg/g dry weight. Significantly 
elevated levels of this amino acid also correlated with significant (twofold) inhibition of mycelial growth. Increases 
in the concentration of mycelial Se-methyl-seleno-l-cysteine appeared to be highly correlated with the enhanced 
biosynthesis of selenomethionine and total selenium content in mycelium.
Conclusions: We have demonstrated that in L. edodes, enhanced biosynthesis of this non-protein amino acid elimi-
nates excess selenium.
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Background
Nearly four decades ago, a significant inverse correlation 
between human cancer mortality and dietary selenium 
intake was reported by Schrauzer and White (Schrauzer 
and White 1978); the level of selenium in whole blood 
is directly proportional to dietary selenium intake. Sele-
nium is, therefore, a trace element that appears to func-
tion as a key nutrient in cancer chemoprevention (Vinceti 
et al. 2014). This important health effect is connected to 
stimulation of the immune system, protection of cells 
against the effects of free radicals by selenium-dependent 
antioxidant enzymes, and inhibition of tumor cell growth 
by selenium metabolites (El-Bayoumy 2001; Rayman 
2005; Brozmanova et al. 2010). Despite its benefits, sele-
nium has a narrow margin of safety that limits the doses 
used in chemoprevention (Reid et al. 2004).
The bioavailability, tissue distribution, and toxicity of 
selenium strongly depend on the form ingested. Organic 
forms of selenium have higher bioavailability and lower 
toxicity than inorganic species (Brozmanova et al. 2010). 
For a long time, l-selenomethionine (SeMet) (Fig. 1) was 
considered to be the organic selenium compound with 
the most potent anticancer activity (Schrauzer 2000). 
That opinion seemed to be confirmed by experiments 
conducted by Clark et al. (Clark et al. 1996), who deter-
mined that supplementation with selenium yeast at a 
dose corresponding to 200 μg of selenium per day appear 
to decrease overall human cancer mortality by 50 % ver-
sus controls. Selenium yeast is a recognized source of 
organic food-form selenium produced by fermenting 
Saccharomyces cerevisiae (baker’s or brewer’s yeast) in 
a selenium-enriched media. Since approximately 85  % 
of selenium in selenium yeast occurs in the form of 
selenomethionine (Ip et  al. 2000), the anticancer effect 
seemed to be due to selenomethionine (Redman et  al. 
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1998). To confirm these initial findings, the largest-ever 
prostate cancer prevention trial, the Selenium and Vita-
min E Cancer Prevention Trial (SELECT), was designed 
and carried out. Selenium was administered orally in 
the form of selenomethionine at a dose of 200 μg for a 
planned follow-up of a minimum of 7 years and a maxi-
mum of 12 years. Initially, SELECT uncovered no reduc-
tion in the risk of prostate cancer following ingestion of 
selenium or vitamin E supplements but did detect a sta-
tistically nonsignificant increase in prostate cancer risk 
with vitamin E ingestion (Lippman et al. 2009). Updated 
data from SELECT confirmed these preliminary results 
(Klein et al. 2011; Kristal et al. 2014).
The substantial differences between the results of Clark 
et  al. (Clark et  al. 1996) and the results of the SELECT 
project indicate that selenomethionine was most likely 
not the molecule primarily responsible for the extremely 
favorable protective activity of selenium yeast against 
cancer (Sharma and Amin 2013). The more recent anti-
cancer research focused on Se-methyl-seleno-l-cysteine 
(MeSeCys) (Fig. 1). Numerous studies have demonstrated 
the efficacy of this non-protein selenoamino acid in pre-
venting and treating cancer (Bhattacharya 2011; Ray-
man 2005; Rayman 2012). Se-methyl-seleno-l-cysteine 
in garlic and broccoli has been shown to more efficiently 
reduce the incidence of mammary and colon cancer in 
rats than selenomethionine in yeast or broccoli supple-
mented with selenite (Finley et al. 2001). This effect may 
be due to substantial differences in the mechanisms of 
chemoprevention by Se-methyl-seleno-l-cysteine and 
other selenocompounds (Suzuki et al. 2010).
Lentinula edodes (Berk.) Pegler, the shiitake mush-
room, is both medicinal and edible. The antitumor 
activity of lentinan and other pharmacologically active 
polysaccharides and polysaccharide-protein complexes in 
the shiitake extracts results mainly from activation of the 
host immune system (Zhang et al. 2005). The mechanism 
by which selenium exerts anticancer and immunomodu-
latory activities differs from the action of L. edodes poly-
saccharide fractions, but similar pharmacological effects 
suggest that these agents may act synergistically. There-
fore, we hypothesized that high concentrations of the 
organic forms of selenium in L. edodes biomass would 
increase the immune system-enhancing and anticancer 
activities of L. edodes extracts.
We previously demonstrated that submerged cultiva-
tion of L. edodes effectively caused selenium from the 
cultivation medium to accumulate in mycelia in the form 
of organic compounds such as selenomethionine, sele-
nocysteine and Se-containing polysaccharides (Turło 
et  al. 2007, 2010). The current study sought to deter-
mine whether L. edodes mycelia grown in medium sup-
plemented with selenium accumulate this element in 
the form of Se-methyl-seleno-l-cysteine and to identify 
the optimum concentration of selenium in the culture 
medium for Se-methyl-seleno-l-cysteine biosynthesis.
Methods
Microorganisms and cultivation media
The Lentinula edodes (Berk.) Pegler strain used in this 
study was American Type Culture Collection (ATCC, 
Manassas, USA) strain 48085. The seed culture was 
grown under the conditions described previously (Suzuki 
et al. 2010; Zhang et al. 2005).
Optimization of culture medium 
for Se‑methyl‑seleno‑l‑cysteine biosynthesis
We used the culture medium optimized in our previous 
research for biosynthesis of SeMet, containing 5  % glu-
cose, 1 % yeast extract, 1.5 % soybean extract, and 0.1 % 
(w/v) KH2PO4 (Turło et al. 2010). The medium was either 
not fortified or enriched with selenium to a concentration 
of 5, 10, 15, 20, or 30 μg/mL via the addition of sodium 
selenite. Fermentation medium was inoculated with the 
seed culture at 10  % (v/v) and cultivated at 26  °C on a 
rotary shaker at 110  rev/min for 14  days. Mycelia were 
harvested via filtration, freeze dried, and used to deter-
mine the concentration of Se-methyl-seleno-l-cysteine.
Extraction of Se‑methyl‑seleno‑l‑cysteine
Against decomposition of Se-methyl-seleno-l-cysteine, 
extraction was performed at 4  °C (Arnault and Auger 
2006). Twenty milliliters of 50  mM HCl were added to 
0.5 g of homogenized mycelia and sonicated for 20 min. 
The mixture was then stirred for 6 h at 4  °C and stored 
at 4  °C. The samples were filtered under reduced pres-
sure, the filtrate was freeze-dried, and the resulting dry 
extract was stored at 4 °C in the dark. Dried extract was 
redissolved in water to the appropriate concentration for 
determination of MeSeCys.
Analytical determination of Se‑methyl‑seleno‑l‑cysteine
Determination of Se-methyl-seleno-l-cysteine was per-
formed with high-performance liquid chromatography 
(HPLC) of o-phthaldialdehyde derivative, compared 
with the retention time of a Se-methyl-seleno-l-cysteine 
standard (Sigma, Saint Louis, USA). Our method was a 
modification of reported previously (Turło et al. 2007).
Fig. 1 The structures of: a l-selenomethionine and b Se-methyl-
seleno-l-cysteine
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Samples were prepared by dissolving 0.1 g of mycelium 
extract in 10 ml of HPLC-grade water. The assay was per-
formed using a calibration curve (external standard). Se-
methyl-seleno-l-cysteine recovery under the conditions 
of extraction and analysis was determined by subject-
ing the standard to the same procedure as the samples. 
HPLC was carried out using a Shimadzu Manufacturing 
INC (Canby, USA) gradient system (SCL-10AVP con-
troller, two LC-10ATVP pumps, CTO-10ACVP oven) 
with a fluorescence detector (LaChrom L-7480, Merck-
Hitachi, Darmstadt, Germany). C18 column 250 × 4 mm; 
Phenomenex (Torrance, USA), Luna 2 with appropriate 
guard column was used. Eluent A consisted of 50  mM 
sodium acetate buffer (pH 7.0) containing 0.1 % acetoni-
trile while eluent B was methanol. The gradient break-
points (min/%B) were (0/40), (6/45), (12/45), (20/63), 
(38/63), and (49/100). The temperature was 32  °C, 
the injection volume was 20  μL, and the flow rate was 
1.2 mL/min. The excitation wavelength was 340 nm, and 
the emission wavelength was 435 nm. Se-methyl-seleno-
l-cysteine retention occurred at 14.9 min.
Analytical determination of selenomethionine
Selenomethionine content was determined by reverse-
phase HPLC of o-phthaldialdehyde derivative (OPA 
method) as previously described (Turło et al. 2007). The 
conditions of the analysis were as follows:
Eluent A was 100  mM sodium acetate buffer pH 7.2 
containing 0.1 % of acetonitrile, eluent B was methanol.
The gradient breakpoints were as follows (min/%B): 
(0/45), (6/45), (12/50), (20/63), (38/63), (49/100), 
(55/100). Temperature was 32 °C, injection volume 20 μL 
and flow rate 1.2  mL/min. The chosen excitation wave-
length was 340 nm and emission wavelength 435 nm. The 
selenomethionine retention time was 40.2 min.
Analytical determination of total selenium
Reverse-phase HPLC of mineralized samples was used 
to determine the total selenium content, as previously 
described (Turło et al. 2009). Namely, a 0.1 % solution of 
diaminonaphthalene (DAN) in 0.1 M HCl was prepared 
and stored in the dark at 4 °C. The pH of each of digested 
sample dissolved in 8 mL of Suprapur water was adjusted 
to 1.8–2 by adding HCl or 7 M NH3·H2O, as needed. One 
milliliter of DAN was added to each sample and the mix-
tures were heated for 45 min at 75 °C. After cooling, 3 mL 
of cyclohexane was added and the samples were shaken 
vigorously for 1  min to extract the fluorescent piazsele-
nol. Prior to RP HPLC determination the samples were 
stored in the dark. The sample solutions were diluted 
with cyclohexane as needed. A blank digest was manip-
ulated similarly for use as a control. Selenium standard 
solutions (6.25–1000 ng Se/mL) were prepared under the 
same conditions. The fluorescence was a linear function 
of the concentration of Se in the tested range (correlation 
coefficient, R = 0.999).
The RP-HPLC conditions were as follows: eluent, ace-
tonitrile: flow rate, 1.4  mL/min; temperature, 25  °C; 
injection volume, 20  μL. For fluorimetric analysis, the 
excitation wavelength was 378  nm and emission wave-
length was 557  nm. The piazselenol retention time was 
3.1 min.
Statistical analysis
Data were analyzed using one-way analysis of variance or 
t Student test with the statistical package STATISTICA 
10 (StatSoft). Arcsine transformation was used to equal 
variances before one-way analysis of variance. Post-hoc 
analysis was performed with the least-significant differ-
ence test. Cell viability data were analyzed using t Stu-
dent test. Differences were considered to be significant 




Cold extraction (with 50  mM HCl at 4  °C) was chosen 
in order to avoid decomposition of Se-methyl-seleno-
l-cysteine in the resulting extract. Se-methyl-seleno-
l-cysteine is stable at room temperature, but extraction 
at high temperature cause its substantial loss. In general, 
organic selenium species remain stable for up to 1  year 
in aqueous solution at pH 4.5 when stored at 4–20  °C 
in the dark (Amoako et  al. 2007). Extraction overnight 
at 4 °C in 50 mM HCl (2:1 v/w) was previously used for 
routine quantification of Se-methyl-seleno-l-cysteine in 
plant samples (Ellis et al. 2004). The current applications 
are the first use of this cold method for the isolation of 
this non-protein amino acid from fungal biomass. When 
developing the extraction method, we have tested the 
recovery of MeSeCys under different conditions. Under 
low-temperature (4  °C) extraction conditions the recov-
ery of MeSeCys was 98.8 % (±2.3 %), while at a tempera-
ture of 100  °C (Soxhlet extraction)—only 4  % (±1.2  %), 
n = 5.
Determination of amino acids with high-performance 
liquid chromatography (HPLC) of o-phthaldialdehyde 
derivatives is described as a method of good selectiv-
ity and efficiency (Hammel et  al. 1997; Bartolomeo and 
Maisano 2006). The standard HPLC equipment and rela-
tively cheap C18 columns used are significant advantages 
of this approach. The detection limit for most of the OPA 
amino acid derivatives is in range 25–50  fmol (Ham-
mel et al. 1997). In our previous research, we successfully 
applied this method for determination of selenomethio-
nine in mycelial hydrolysates (Turło et al. 2007). Currently, 
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this approach was successfully used for determination of 
Se-methyl-seleno-l-cysteine. The detection limit (LOD) 
for the OPA Se-methyl-seleno-l-cysteine derivative was 
63  fmol, limit of quantification (LOQ)—211  fmol. The 
fluorescence was a linear function of the concentration 
of MeSeCys in the tested range of 0–25 nmol/mL (corre-
lation coefficient R =  0.999, equation for standard curve 
was y  =  2.182E−06x, where y-MeSeCys concentration, 
x—peak area). The reproducibility of the method was 
assessed by calculating the relative standard deviations 
for MeSeCys standard solutions (n = 5); the values ranged 
from 1.35 to 4.1  %. The standard deviation of the blank 
was used to estimate the detection and quantification 
limits of the complete procedure. The lowest determined 
MeSeCys concentration in the mycelial extract was 79 pM, 
thus it was nearly 400-fold higher than limit of quantifica-
tion (LOQ). The Fig. 2 shows the representative chroma-
tograms of the extract from not Se-enriched mycelium, 
the extract from mycelium cultivated in medium enriched 
with 20 μg/mL Se and the mixture of extract from not Se-
enriched mycelium with MeSeCys standard solution.
Effect of medium supplementation on mycelial growth
The medium that we selected on the ground of the pre-
vious research was associated with a satisfactory yield 
of mushroom mycelium (10  g of dry weight/1  L of the 
medium after 10  days of cultivation) (Table  1). Accord-
ing to our previous results increasing the selenium 
concentration (in the form of sodium selenite) had a 
dose-dependent inhibitory effect on mycelial growth 
(Turło et  al. 2007, 2010). When the concentration sele-
nium in the medium was greater than 15  μg/mL, the 
mycelial growth decreased.
Biosynthesis of Se‑methyl‑seleno‑l‑cysteine in L. edodes
We wanted to evaluate whether the presence of sodium 
selenite in medium stimulated biosynthesis of MeSeCys 
by mycelium of L. edodes and, if so, to find the optimal 
concentration. The concentration of Se-methyl-seleno-
l-cysteine rose from not detectable content in mycelium 
cultivated in non-enriched medium to 120 μg/g dry mass 
of mycelium grown in medium enriched with 20 μg/mL 
of Se. When the concentration of Se in the medium was 
greater than 20 μg/mL, Se-methyl-seleno-l-cysteine con-
tent in the mycelium decreased (Table 1).
Biosynthesis of selenomethionine in L. edodes
The amount of selenomethionine in the harvested myce-
lial biomass increased with the increasing concentration 
of selenium. The optimum concentration was 20 μg/mL, 
which provided a concentration of 672 μg/g dry mass in 
the harvested mycelium. Higher concentrations of sele-
nium inhibited selenomethionine biosynthesis (Table 1).
Discussion
Despite the sizeable interest, the metabolism of selenium 
by higher fungi remains poorly understood. This process 
is most widely characterized in plants, motivating us 
to compare our data on the biosynthesis of Se-methyl-
seleno-l-cysteine in L. edodes with reports concerning 
plants. According to Ellis and Salt (Ellis and Salt 2003), 
plants primarily take up selenium as selenate or selenite, 
which are then metabolized via the sulfur assimilation 
pathway to yield selenomethionine, selenocysteine, and 
other selenium analogs of various sulfur metabolites. 
Non-specific incorporation of selenoamino acids into 
proteins is thought to contribute to selenium toxicity 
(Ellis et al. 2004). A proposed mechanism of selenium tol-
erance in plants is the specific conversion of potentially 
toxic selenoamino acids into non-protein derivatives 
such as Se-methyl-seleno-l-cysteine (Wang et  al. 1999). 
Our previous studies indicated that L. edodes can incor-
porate selenium into the proteins, mainly in the form of 
selenomethionine (Turło et  al. 2007). Toxicity occurred 
when selenomethionine was present at >300 µg/g of fun-
gal biomass and a total selenium content of 1100  µg/g, 
resulting in substantial inhibition of mycelial growth 
(Turło et al. 2010). We also found that excess selenium is 
eliminated via its reduction to elemental selenium (Turło 
et al. 2010), what was 2 years later confirmed by Tsivileva 
et al. (2012).
In the current study by optimizing the concentration 
of selenium in the culture medium, we increased the 
mycelial concentration of Se-methyl-seleno-l-cysteine 
from essentially non-detectable levels to 120  μg/g D.W. 
(Table 1). However, only 4–11 % of the selenium accumu-
lated in the form of Se-methyl-seleno-l-cysteine (Fig. 3).
Increases in the concentration of mycelial Se-methyl-
seleno-l-cysteine appeared to be highly correlated with 
the enhanced biosynthesis of selenomethionine. Met-
SeCys content in cultivated mycelia also rose as total 
selenium content increased (Table  1). As it was stated 
above, the MeSeCys contents in mycelium well correlate 
with the total selenium and SeMet. The presented graph 
(Fig.  4) indicates for selenium content up to 1000  μg/g 
and the MetSeCys up to 300 μg/g the correlation is linear 
(r = 0.992, p < 0.005, r = 0.997, p < 0.001) while for the 
higher concentrations nonlinear.
(See figure on next page.) 
Fig. 2 Representative chromatograms of: a extract from not Se-enriched mycelium, b mixture of extract from not Se-enriched mycelium with 
MeSeCys standard solution, c extract from mycelium cultivated in medium enriched with 20 μg/mL Se
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It suggests that elimination of excess selenium via 
SeMet and MetSeCys biosynthesis is not the sole way of 
detoxification in the case of high selenium concentration. 
As mentioned above, in high selenium concentrations, 
the excess selenium is also eliminated via its reduction to 
elemental red selenium (Turło et al. 2010; Tsivileva et al. 
2012). It can be assumed that, as in plants, incorporation 
of selenomethionine into the structures of mushroom 
proteins likely contributes to selenium toxicity: myce-
lial growth was significantly reduced (p  <  0.0005) when 
the concentration of selenomethionine in the mycelia 
was >300 µg/g of dry mass. This effect was accompanied 
Table 1 Relationship between the selenium concentration in the culture medium and the total selenium, selenomethio-
nine and Se-methylselenocysteine contents in L. edodes mycelia
Standard error are given in parentheses. n = 5 replicates
Within columns, values bearing different subscript letters were significantly different from each other (p < 0.05)
Concentration values for mycelium components are expressed in μg/g of mycelial dry weight
Mycelium growth is given in grams of mycelial dry weight/1 L of culture medium














































Fig. 3 Percentage of selenium accumulated in the form of Se-
methyl-seleno-l-cysteine against the total content of selenium in the 
mycelium
Fig. 4 Correlation of Se-methyl-seleno-l-cysteine content in myce-
lium with a selenomethionine. content and b total selenium content 
in cultivated mycelia
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by a nearly twofold increase in the concentration of Se-
methyl-seleno-l-cysteine (Table  1). These observations 
are consistent with the assumption that the biosynthe-
sis of non-protein derivatives of selenium is a method of 
detoxification.
Conclusions
Here we have demonstrated that in the Basidiomycetes 
fungus L. edodes, enhanced biosynthesis of the non-
protein amino acid Se-methyl-seleno-l-cysteine elimi-
nates excess selenium. Significantly elevated levels of this 
amino acid correlated with significant (twofold) inhibi-
tion of mycelial growth. By optimizing the concentra-
tion of selenium in the culture medium, we increased the 
mycelial concentration of Se-methyl-seleno-l-cysteine 
from essentially non-detectable levels to 120  µg/g dry 
weight. The further problem is to examine whether, 
according to our hypothesis, high concentration of 
MeSeCys in extracts of the fungus increases the anti-can-
cer effect.
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